. John Trawick and Elitra Pharmaceuticals for permitting us to
show his outstanding Phase I and Phase II SBIR applications. Dr. Trawick submitted his
Phase I application as a new investigator in December 1999, and his Phase II
application in April 2002.
To avoid confusing current applicants, we have updated his original SBIR Phase I form
pages onto those of the PHS 398 which are required today. We have also made some
minor changes in personnel names and deleted confidential salary information. Other
than these minor changes, the applications are exactly as submitted.
We have also included the Summary Statement and Notice of Grant Award for each
application. Further, we've added annotations to explain how these application reflect
much of the advice we give in our "
Advice on SBIR and STTR Grant Applications
."
NIAID annotations are in
yellow boxes, like this one.
Please note that these applications are copyrighted. They may be used
for non-profit educational purposes provided the documents remain
intact and unchanged and both Elitra Pharmaceuticals and NIAID are
credited.
If you have questions or comments, please contact:
Gregory Milman, Ph.D.
Director, Office for Innovation and Special Programs
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases, NIH, DHHS
6700-B Rockledge Drive; Room 2140
Bethesda, MD 20892-7610 (US Mail)
Rockville, MD 20817-7610 (Delivery Services)
Tel (301) 496-8666 Fax (301) 402-0369
Email gmilman@niaid.nih.gov Form Approved Through 05/2004
OMB No.
0925-0001
PHS 398 (Rev. 05/01)
Face Page
Form Page 1
Department of Health and Human Services
LEAVE BLANKFOR PHS USE ONLY.
Public Health Services
Type
Activity
Number
Grant Application
Review Group
Formerly
Do not exceed 56-character length restrictions, including spaces.
Council/Board (Month, Year)
Date Received
1. TITLE OF PROJECT

2. RESPONSE TO SPECIFIC REQUEST FOR APPLICATIONS OR PROGRAM ANNOUNCEMENT OR SOLICITATION
NO
YES
(If Yes, state number and title)
Number:

Title:

3. PRINCIPAL INVESTIGATOR/PROGRAM DIRECTOR
New Investigator
No
Yes
3a. NAME (Last, first, middle)

3b. DEGREE(S)

3c. POSITION TITLE

3e. DEPARTMENT, SERVICE, LABORATORY, OR EQUIVALENT

3f. MAJOR SUBDIVISION

3d. MAILING ADDRESS (Street, city, state, zip code)








3g. TELEPHONE AND FAX (Area code, number and extension)
TEL:
FAX:

E-MAIL ADDRESS:
4a. Research Exempt
No
Yes
If Yes, Exemption No.

5. VERTEBRATE ANIMALS
No
Yes
4. HUMAN SUBJECTS
RESEARCH
No
Yes
4b. Human
Subjects
Assurance No.

4c. NIH-defined Phase III
Clinical Trial

No
Yes
5a. If Yes, IACUC approval Date

5b. Animal welfare assurance no

6. DATES OF PROPOSED PERIOD OF
SUPPORT

(month, day, yearMM/DD/YY)
7. COSTS REQUESTED FOR INITIAL
BUDGET
PERIOD
8. COSTS REQUESTED FOR PROPOSED
PERIOD OF SUPPORT
From
Through
7a. Direct Costs ($)
7b. Total Costs ($)
8a. Direct Costs ($)
8b. Total Costs ($)






9. APPLICANT ORGANIZATION
10. TYPE OF ORGANIZATION
Name
Public:
Federal
State
Local
Private:

Private Nonprofit
For-profit:
General
Small Business
Woman-owned
Socially and Economically Disadvantaged
11. ENTITY IDENTIFICATION NUMBER

Address





DUNS NO. (if available)
Institutional Profile File Number (if known)

Congressional District
12. ADMINISTRATIVE OFFICIAL TO BE NOTIFIED IF AWARD IS MADE
13. OFFICIAL SIGNING FOR APPLICANT ORGANIZATION
Name

Name

Title

Title


Address






Address






Tel

FAX

Tel

FAX

E-Mail

E-Mail

14. PRINCIPAL INVESTIGATOR/PROGRAM DIRECTOR ASSURANCE: I certify that the
statements herein are true, complete and accurate to the best of my knowledge. I am
aware that any false, fictitious, or fraudulent statements or claims may subject me to
criminal, civil, or administrative penalties. I agree to accept responsibility for the scientific
conduct of the project and to provide the required progress reports if a grant is awarded as
a result of this application.
SIGNATURE OF PI/PD NAMED IN 3a.
(In ink. Per signature not acceptable.)
DATE
15. APPLICANT ORGANIZATION CERTIFICATION AND ACCEPTANCE: I certify that the
statements herein are true, complete and accurate to the best of my knowledge, and
accept the obligation to comply with Public Health Services terms and conditions if a grant
is awarded as a result of this application. I am aware that any false, fictitious, or fraudulent
statements or claims may subject me to criminal, civil, or administrative penalties.
SIGNATURE OF OFFICIAL NAMED IN 13.
(In ink. Per signature not acceptable.)
DATE
Title describes project.
SBIR Phase I and II applications must use PHS398 form pages
Indicates response to SBIR solicitation.
Dominant expression for new targets in Candida albicans PHS 2003-2
Phase I SBIR Trawick, John D.
Ph.D.
Senior Research Scientist
Elitra Pharmaceuticals, Inc.
3510 Dunhill Street
San Diego, CA 92121
jtrawick@elitra.com
858-410-3019
858-410-3090 07/01/00
01/01/02
$94,466
$100,000
Elitra Pharmaceuticals, Inc.
3510 Dunhill Street
San Diego, CA 92121 33-0779254
46
Harry F. Hixson
President and CEO
Elitra Pharmaceuticals, Inc.
3510 Dunhill Street
San Diego, CA 92121
858-410-3030
858-410-3090
hhixson@elitra.com
Copyright 2003, Elitra Pharmaceuticals Principal Investigator/Program Director (Last, first, middle):
PHS 398 (Rev. 05/01)
Page _2___
Form Page 2
DESCRIPTION: State the applications broad, long-term objectives and specific aims, making reference to the health relatedness of the project. Describe
concisely the research design and methods for achieving these goals. Avoid summaries of past accomplishments and the use of the first person. This abstract
is meant to serve as a succinct and accurate description of the proposed work when separated from the application. If the application is funded, this
description, as is, will become public information. Therefore, do not include proprietary/confidential information.
DO NOT EXCEED THE SPACE
PROVIDED.
PERFORMANCE SITE(S) (organization, city, state)








KEY PERSONNEL. See instructions. Use continuation pages as needed to provide the required information in the format shown below.
Start with Principal Investigator. List all other key personnel in alphabetical order, last name first.
Name Organization
Role
on
Project

































Disclosure Permission Statement. Applicable to SBIR/STTR Only. See instructions.
Yes
No

Kept very simple. Avoids description of confidential
information. Shows linkage with Phase II. Would be better
with a list of specific aims.
Trawick, John D.
A screen for dominant negative genes will be used to identify targets and pathways in Candida albicans. The
genes and pathways identified will be developed as new antifungal targets. An expression vector system
suitable for screening libraries in C. albicans has been devised. Phase I of this project includes final
construction and optimization of the expression vector and construction of cDNA libraries capable of
identifying dominant negative mutants. Preliminary screening will begin in Phase I. Phase II of the project
will entail identifying essential genes and processes by dominant negative mutagenesis and to develop
screens for new antifungals based on these essential genes. The method proposed for identifying essential
genes is ideal for C. albicans, a diploid human pathogen not normally amenable to genetic analysis, and can
be automated.
Elitra Pharmaceuticals, Inc.
3510 Dunhill Street
San Diego, CA 92121
John D. Trawick, Ph.D.
Elitra Pharmaceuticals, Inc.
Principal Investigator
J. Gordon Foulkes, Ph.D.
Elitra Pharmaceuticals, Inc.
Co-Investigator
Sherry Nouraini
Elitra Pharmaceuticals, Inc.
Postdoctoral Fellow
Carlos Zamudio
Elitra Pharmaceuticals, Inc.
Collaborator
William A. Fonzi, Ph.D.
Georgetown University
Consultant Copyright 2003, Elitra Pharmaceuticals Principal Investigator/Program Director (Last, first, middle):

PHS 398 (Rev. 05/01)
Page _______
Form Page 3
The name of the principal investigator/program director must be provided at the top of each printed page and each continuation page.
RESEARCH GRANT
TABLE OF CONTENTS
Page Numbers
Face Page ..................................................................................................................................................
1
Description, Performance Sites, and Personnel ...................................................................................
2-
Table of Contents ..................................